ORMP finished down 4% today; the company PR’d that its phase-2 oral-insulin trial was a success, but many investors are evidently skeptical: http://blogs.marketwatch.com/health-exchange/2014/01/30/orameds-oral-insulin-tests-are-positive-but-investors-are-skittish/ There is ample reason to be skeptical insofar as the company’s PR furnished no clinical data (http://finance.yahoo.com/news/oramed-announces-successful-fda-phase-090000076.html ).